SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10443	Companies
219247	Keywords
148701	Articles
115972	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 09/17/2025 at 07:00, 8 months 6 days ago

Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sanofi's brivekimig shows positive results in phase 2a study for hidradenitis suppurativa, presenting clinically meaningful improvements in primary and secondary endpoints in biologic-naïve patients

Sanofi Brivekimig Hidradenitis Suppurativa Phase 2a Study Immune-mediated Diseases
PRESS RELEASE

published on 09/15/2025 at 18:30, 8 months 8 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 09/12/2025 at 18:35, 8 months 11 days ago

Sanofi Publishes Voting Rights Data for August 2025

Voting Rights Actions Financial Markets Sanofi August 2025
PRESS RELEASE

published on 09/12/2025 at 18:30, 8 months 11 days ago

Sanofi: Information concerning the total number of voting rights and shares - August 2025
Sanofi discloses total number of voting rights and shares as per French regulations. Details available on Sanofi's website

Voting Rights Shares French Regulations Disclosure Sanofi
BRIEF

published on 09/11/2025 at 07:05, 8 months 12 days ago

Sanofi Obtains Fast Track Designation for SAR402663 in the United States

FDA Gene Therapy Sanofi Fast Track AMD
BRIEF

published on 08/29/2025 at 23:55, 8 months 24 days ago

Sanofi’s Wayrilz Gets FDA Approval as First BTK Inhibitor for ITP

FDA Approval Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia
PRESS RELEASE

published on 08/29/2025 at 23:50, 8 months 24 days ago

Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia. Novel treatment targets BTK through multi-immune modulation to address root causes of ITP, providing rapid and durable platelet response and improved symptoms

Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia LUNA 3 Study
PRESS RELEASE

published on 08/25/2025 at 18:30, 8 months 29 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/18/2025 at 18:35, 9 months 5 days ago

Sanofi Reports Total Shares and Voting Rights for July 2025

Voting Rights French Commercial Code Shares 2025 Sanofi
PRESS RELEASE

published on 08/18/2025 at 18:30, 9 months 5 days ago

Sanofi: Information concerning the total number of voting rights and shares - July 2025
Sanofi discloses total voting rights and issued shares as per French commercial and stock market regulations. Details available on their website

Voting Rights Shares French Regulations Investor Relations Sanofi

Accesswire

Published on 05/23/2026 at 19:45, 2 hours 56 minutes ago

Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 19 hours 26 minutes ago

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 19 hours 41 minutes ago

Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 20 hours 16 minutes ago

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 20 hours 16 minutes ago

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

View all ACCESSWIRE

EQS Group

Published on 05/23/2026 at 16:30, 6 hours 10 minutes ago

HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 6 hours 44 minutes ago

EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 2 hours ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 1 day 4 hours ago

Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring

Les Echos

Published on 05/22/2026 at 18:05, 1 day 4 hours ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 9 hours ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Published on 05/22/2026 at 08:30, 1 day 14 hours ago

Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
Published on 05/21/2026 at 17:50, 2 days 4 hours ago

CDA - H1 results 2025 2026
Published on 05/21/2026 at 17:45, 2 days 4 hours ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE